The current role of model-based drug development

被引:15
|
作者
Suryawanshi, Satyendra [1 ]
Zhang, Liping [2 ]
Pfister, Marc [2 ]
Meibohm, Bernd [1 ]
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Coll Pharm, Memphis, TN 38163 USA
[2] Bristol Myers Squibb Res & Dev, Princeton, NJ USA
关键词
drug development; modeling; pharmacodynamics; pharmacokinetics; simulation; CLINICAL-TRIAL SIMULATION; QUANTITATIVE PHARMACOLOGY; LABELING DECISIONS; DARBEPOETIN-ALPHA; INTEGRATION; DISEASE; BIOMARKERS; APPROVAL; IMPACT;
D O I
10.1517/17460441003713470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Current drug discovery and development programs are under growing scrutiny for low productivity and escalating costs. Model-based drug development (MBDD) has been recognized as a promising tool to address some of the related challenges. Areas covered in this review: This review introduces the concept of MBDD and the associated quantitative pharmacology-based iterative 'learn and confirm' paradigm in the drug discovery and development process to provide concise information for rational decision making. It summarizes the evolving role of MBDD in drug development programs and outlines the full armamentarium of modeling and simulation approaches utilized to facilitate its application. What the reader will gain: Different aspects and applications of MBDD are introduced to the reader and illustrated in prime examples. The reader is provided with an understanding of potential applications of MBDD in drug development as well as the associated limitations and challenges in its implementation. Take home message: MBDD is a tool that is increasingly used throughout the drug discovery and development continuum to support fast and rationale decision making and has thereby the potential to accelerate and increase the cost-effectiveness of the drug development process.
引用
收藏
页码:311 / 321
页数:11
相关论文
共 50 条
  • [1] Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
    Zhang, Liping
    Pfister, Marc
    Meibohm, Bernd
    AAPS JOURNAL, 2008, 10 (04) : 552 - 559
  • [2] Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
    Liping Zhang
    Marc Pfister
    Bernd Meibohm
    The AAPS Journal, 2008, 10 : 552 - 559
  • [3] Model-based clinical drug development in the past, present and future: a commentary
    Kimko, Holly
    Pinheiro, Jose
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (01) : 108 - 116
  • [4] Model-based drug discovery: implementation and impact
    Visser, Sandra A. G.
    Aurell, Malin
    Jones, Rhys D. O.
    Schuck, Virna J. A.
    Egnell, Ann-Charlotte
    Peters, Sheila A.
    Brynne, Lena
    Yates, James W. T.
    Jansson-Lofmark, Rasmus
    Tan, Beesan
    Cooke, Marie
    Barry, Simon T.
    Hughes, Andrew
    Bredberg, Ulf
    DRUG DISCOVERY TODAY, 2013, 18 (15-16) : 764 - 775
  • [5] Improving Productivity With Model-Based Drug Development: An Enterprise Perspective
    Grasela, T. H.
    Slusser, R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (02) : 263 - 268
  • [6] Model-based drug development: application of modeling and simulation in drug development
    Kim T.H.
    Shin S.
    Shin B.S.
    Journal of Pharmaceutical Investigation, 2018, 48 (4) : 431 - 441
  • [7] Model-based drug development applied to oncology
    Barrett, Jeffrey S.
    Gupta, Manish
    Mondick, John T.
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (02) : 185 - 209
  • [8] Model-Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry
    Stone, Julie A.
    Banfield, Christopher
    Pfister, Marc
    Tannenbaum, Stacey
    Allerheiligen, Sandy
    Wetherington, Jeffrey D.
    Krishna, Rajesh
    Grasela, Dennis M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09) : 20S - 30S
  • [9] Model-Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development
    Wetherington, Jeffrey D.
    Pfister, Marc
    Banfield, Christopher
    Stone, Julie A.
    Krishna, Rajesh
    Allerheiligen, Sandy
    Grasela, Dennis M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09) : 31S - 46S
  • [10] Implementing a domain-specific language for model-based drug development
    Kokash, Natallia
    Moodie, Stuart L.
    Smith, Mike K.
    Holford, Nick
    6TH INTERNATIONAL CONFERENCE ON EMERGING UBIQUITOUS SYSTEMS AND PERVASIVE NETWORKS (EUSPN 2015)/THE 5TH INTERNATIONAL CONFERENCE ON CURRENT AND FUTURE TRENDS OF INFORMATION AND COMMUNICATION TECHNOLOGIES IN HEALTHCARE (ICTH-2015), 2015, 63 : 308 - 316